Everolimus as treatment for breast cancer patients with bone metastases only: results of the phase II RADAR study

Abstract

The RADAR study is mainly hypothesis generating. It suggests that everolimus has single-agent activity, and patients with bone metastases only may retrieve long-term benefit from everolimus if they do not progress within 8 weeks of treatment.

Risk of oral and gastrointestinal mucosal injury in patients with solid tumors treated with everolimus, temsirolimus or ridaforolimus: a comparative systematic review and meta-analysis

“…The above-studied adverse events are considered an important cause for treatment interruption and/or discontinuation in clinical trials [12][13][14]. There is currently no agreed-upon method to predict a patient at highest risk, and therefore, regular monitoring of patients is warranted.…”

“…André et al (2014) [33] Bachelot et al (2012) [29] Baselga et al (2009) [42] Baselga et al (2012) [30] Bissler et al (2013) [28] Demetri et al (2013) [38] Franz et al (2013) [26] Hess et al (2009) [36] Hudes et al (2007) [37] Huober et al (2013) [25] Maass et al (2013) [12] Motzer et al (2013) [13] Ohtsu et al (2013) [32] Pavel et al (2011) [10] Rini et al (2014) [27] Wolf et al (2013) [31] Yao et al (2011) [35] Zhu et al (2014) [34] …”

“…Baselga et al (2009) [42] Baselga et al (2012) [30] Bissler et al (2013) [28] Demetri et al (2013) [38] Franz et al (2013) [26] Hess et al (2009) [36] Hudes et al (2007) [37] Huober et al (2013) [25] Maass et al (2013) [12] Motzer et al (2013) [13] Ohtsu et al (2013) [32] Pavel et al (2011) [43] Rini et al (2014) [27] Wolf et al (2013) [31] Yao et al (2011) [35] Zhu et al (2014) [34] Total events Heterogeneity: Tau 2 = 0.10; Chi 2 = 55.51, df = 16 (p < 0.00001), I 2 = 71% Test for everall effect: Z = 6.74 (p < 0.00001) Bachelot et al (2012) [29] Baselga et al (2009) [42] Baselga et al (2012) [30] Bissler et al (2013) [28] Demetri et al (2013) [38] Franz et al (2013) [26] Hess et al (2009) [36] Hess et al (2009) [36] Hudes et al (2007) [37] Hudes et al (2007) [37] Huober et al (2013) [25] Maass et al (2013) [12] Motzer et al (2013) [13] Ohtsu et al (2013) [32] Pavel et al (2011) [10] Rini et al (2014) [27] Rini et al (2014) [27] Wolf et al (2013) [31] Wolf et al (2013) [31] Yao et al (2011) [35] Zhu et al (2014) …”

Emerging drugs for the treatment of bone metastasis

“…After being stable on 8 weeks of everolimus 10 mg/day, patients were randomized to everolimus-continuation or placebo. Time to progression in patients with everolimus-continuation was 37.0 (95% CI 16.7 --40.3) vs 12.6 weeks (95% CI 7.1 --17.9) with placebo [HR = 0.554 (95% CI: 0.282 --1.09) p = 0.0818] suggesting that patients with bone metastases only may retrieve longterm benefit from everolimus if they do not progress within 8 weeks of treatment [106].…”

mTOR inhibitor therapy: Does it prevent HCC recurrence after liver transplantation?

“…The crucial role of the mTOR pathway in cell growth and survival makes it a logical target for antitumor strategies [26], as borne out by clinical data in various types of malignancy. Everolimus is licensed for the treatment of advanced renal cell carcinoma based on improved progression-free survival [27], and is being investigated for the treatment of certain breast cancers [28][29][30] and other malignancies [31][32][33], while sirolimus has been shown to reduce rates of skin cancer in solid organ transplant recipients [34,35]. The evidence base concerning a potential protective effect of mTOR inhibition on HCC recurrence is, however, more preliminary.…”